Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2427784 | 0.84 | ALDH1A1 (0.57) | ALDH1A1KDM4EHSD17B10LMNASLC6A3 | |
| SCHEMBL29548152 | 0.84 | ALDH1A1 (0.57) | ALDH1A1KDM4EHSD17B10LMNASLC6A3 | |
| SCHEMBL24529118 | 0.82 | MRGPRX4 (0.51) | ALDH1A1KDM4EHSD17B10MRGPRX4LMNA | |
| SCHEMBL28844005 | 0.82 | MRGPRX4 (0.46) | ALDH1A1HSD17B10MRGPRX4KMT2AMEN1 | |
| SCHEMBL30280757 | 0.82 | MRGPRX4 (0.51) | ALDH1A1KDM4EHSD17B10MRGPRX4LMNA | |
| SCHEMBL4324495 | 0.82 | ALDH1A1 (0.47) | ALDH1A1KDM4EHSD17B10LMNASLC6A3 | |
| SCHEMBL2192561 | 0.82 | ALDH1A1 (0.47) | ALDH1A1KDM4EHSD17B10MRGPRX4LMNA | |
| SCHEMBL2619294 | 0.81 | MRGPRX4 (0.50) | ALDH1A1KDM4EHSD17B10MRGPRX4LMNA | |
| SCHEMBL4443811 | 0.81 | MRGPRX4 (0.50) | ALDH1A1KDM4EHSD17B10MRGPRX4LMNA | |
| SCHEMBL1052962 | 0.80 | ALDH1A1 (0.51) | ALDH1A1KDM4EHSD17B10MRGPRX4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966159-A2 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2007-08-02 | — | — | US | disclosed |
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2007-08-02 | — | — | US | disclosed |
| WO-2007071963-A2 | QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | VEGFA, TUBB3, TUBA3C | ALDH1A1 2180/4885KDM4E 3185/4885HSD17B10 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.